HER2-directed Biosimilar in Breast Cancer: Real World ePRO

Clinical trial NCT05234021 · COMPLETED

Trial details

NCT number: NCT05234021
Sponsor: OnkoZentrum Zürich AG
Status: COMPLETED
Study type: OBSERVATIONAL

HER2-positive Breast Cancer Biosimilar Patient Reported Outcome

Start date: 2021-12-14
Primary completion: 2023-06-30
Enrollment: 52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.